UV-spectroscopic methods for estimation of rizatriptan benzoate in pharmaceutical preparations

International Journal of ChemTech Research

Volumn 2, Issue 1, 2010, Pages 653-659

  Kumari, Acharjya Sasmita ^a   Subhasish, Sahoo ^a   Kaushik, Dash Kiran ^a   Annapurna, M M ^a  

^a ROLAND INSTITUTE OF PHARMACEUTICAL SCIENCES   (India)

Author keywords

Rizatriptanbenzoate; Spectrophotometry; Validation

Indexed keywords

RIZATRIPTAN;

ACCURACY; ARTICLE; DRUG FORMULATION; ECONOMIC ASPECT; RELIABILITY; STANDARD; TABLET FORMULATION; ULTRAVIOLET SPECTROSCOPY; VALIDATION PROCESS;

EID: 77953437718     PISSN: None     EISSN: 09744290     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Martindale, The complete drug reference, 34th Edition, 471.
2. Goldberg MR, Rizatriptan, a novel 5-HT 1B/1D agonist for migraine; Single- and multiple- dose tolerability and pharmacokinetics in healthy subjects, journal of clinical pharmacology, 2000, 40, 74-83.
3. Chen J, Jiang X, Jiang W, Mei N, Gao X, Zhang Q .Liquid chromatographic method for the determination of rizatriptan in human plasma, Journal of Chromatography B, Volume 805, Issue 1, 5 June 2004, 169-173.
4. T. Joseph Sunder Raj, Ch. Bharathi, M. Saravana Kumar, Joseph Prabahar, P. Naveen, Identification, isolation and characterization of process-related impurities in Rizatriptan benzoate,Journal of Pharmaceutical and Biomedical Analysis, Volume 49, Issue 1, 15 January 2009, 156-162.
5. Guo JF, Zhang AJ, Zhao L, Sun XH, Zhao YM, Gao HZ, Liu ZY, Qiao SY,Determination of Rizatriptan in human plasma by liquid chromatographic- eletrospray tandem mass spectrometry, Application to a clinical pharmacokinetic study, Biomedical chromatography, 2006 Jan;20(1):61-6.
6. Chen Y, Miao H, Lin M, Fan G, Hong Z, Wu H, Wu Y,Development and validation of a selective and robust LC-MS/MS method for high-throughput quantifying rizatriptan in small plasma samples: Application to a clinical pharmacokinetic study, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2006 Dec 5; 844(2):268-77.
7. B. Mallikarjuna Rao, Sivaiah Sangaraju, M.K. Srinivasu, P. Madhavan, M. Lalitha Devi, P. Rajendra Kumar, K.B. Chandrasekhar, Ch.Arpitha,T. Satya Balaji,Development and validation of a specific stability indicating HPLC method for rizatriptan benzoate . Journal of Pharmaceutical and Biomedical Analysis, Volume 41, Issue 4, 16 June 2006, 1146-1151.
8. I. Gopichand, A. Mittal, R. Kumar Thaper, S. Sivakumar, B. M.Rao, and M. K.Srinivasu, HPLC method for the quantitative determination of Rizatriptan benzoate, an antimigraine agent in pharmaceutical dosage forms and purity evaluation in bulk drugs, www.aapsj.org/abstracts/AM-2003/AAPS2003-001145.PDF.
9. Mira Zecevic, Biljana Jocic, Ljiljana Zivanovic,Ana Protic, Application of Multicriteria Methodology in the Development of Improved RP-LC-DAD for Determination of Rizatriptan and Its Degradation Products, Chromatographia, 2008,68 , 911-918.
10. Kamlesh P. Vyas, Rita A. Halpin, Leslie A. Geer, Joan D. Ellis, Lida Liu, Haiyung Cheng, Cynthia Chavez-Eng, Bogdan K. Matuszewski, Sandor L. Varga, Alexander R. Guiblin, and J. D. Rogers,Disposition and Pharmacokinetics of the Antimigraine Drug, Rizatriptan, in Humans. Drug Metabolism andDisposition, 2000January, Vol.28, Issue1,89-95.